Table 1. Baseline characteristics, demographic data and correlation with clinical and pathologic response.
| Baseline characteristic/demographic variable | Overall | Clinical complete response (cCR) | p-value | Pathologic complete response (pCR) | p-value | ||
|---|---|---|---|---|---|---|---|
| Yes | No | Yes | No | ||||
| 115 | 49 (43.4) | 64 (56.6) | 8 (7.1) | 107 (92.9) | |||
| Age (median, years) | 51.2 | 47.5 | 53.5 | 0.01a | 43.0 | 50.0 | 0.08a |
| Menopausal status | < 0.001b | 0.28c | |||||
| Premenopausal | 60 (52.2) | 35 (71.4) | 24 (37.5) | 6 (75.0) | 54 (50.5) | ||
| Postmenopausal | 55 (47.8) | 14 (28.6) | 40 (62.5) | 2 (25.0) | 53 (49.5) | ||
| Histological subtype | 0.53c | 1.0c | |||||
| Ductal | 98 (86.7) | 42 (85.7) | 54 (87.1) | 8 (100.0) | 90 (85.7) | ||
| Lobular | 9 (8.0) | 3 (6.1) | 6 (9.7) | 0 (0) | 9 (8.6) | ||
| Mixed | 6 (5.3) | 4 (8.2) | 2 (3.2) | 0 (0) | 6 (5.7) | ||
| Histological grade | 0.008b | < 0.001c | |||||
| I–II | 83 (74.1) | 31 (63.3) | 52 (85.2) | 0 (0) | 83 (79.8) | ||
| III | 29 (25.9) | 18 (36.7) | 9 (14.8) | 8 (100.0) | 21 (20.2) | ||
| Initial Tumor staging | 0.06b | 0.04c | |||||
| T2 | 44 (39.3) | 22 (45.9) | 22 (34.4) | 3 (37.5) | 41 (39.4) | ||
| T3 | 31 (27.7) | 16 (33.3) | 15 (23.4) | 5 (62.5) | 26 (25.0) | ||
| T4 | 37 (33.0) | 10 (20.8) | 27 (42.2) | 0 (0) | 37 (35.6) | ||
| Initial Nodal staging | 0.43b | 1.00c | |||||
| N0 | 30 (26.1) | 16 (32.6) | 14 (21.9) | 2 (25.0) | 28 (26.2) | ||
| N1 | 61 (53.0) | 24 (49.0) | 36 (56.2) | 4 (50.0) | 57 (53.3) | ||
| N2–3 | 24 (20.9) | 9 (18.4) | 14 (21.9) | 2 (25.0) | 22 (20.5) | ||
| ER status | 0.19c | 1.0c | |||||
| Negative | 3 (2.6) | 2 (4.1) | 0 (0) | 0 (0) | 3 (2.8) | ||
| Positive (≥ 1%) | 112 (97.4) | 47 (95.9) | 64 (100.0) | 8 (100.0) | 104 (97.2) | ||
| Cells with ER expression: mean, % (SD), | 71.5 (14.1) | 66.0 (27.2) | 75.0 (22.3) | 0.03a | 63.1 (29.6) | 71.7 (24.4) | 0.30a |
| PR status | 0.62c | ||||||
| Negative | 19 (17.0) | 11 (23.4) | 8 (12.5) | 0.13b | 2 (25.0) | 17 (16.4) | |
| Positive (≥ 1%) | 93 (83.0) | 36 (76.6) | 56 (87.5) | 6 (75.0) | 87 (83.6) | ||
| Cells with PR expression: mean, % (SD), | 41.5 (14.1) | 32.4 (31.8) | 46.3 (31.7) | 0.025a | 29.4 (27.3) | 41.4 (32.7) | 0.34a |
| HER2 status | 0.05b | 0.02c | |||||
| Negative | 87 (76.3) | 32 (66.7) | 53 (82.8) | 3 (37.5) | 84 (79.3) | ||
| Positive | 27 (23.7) | 16 (33.3) | 11 (17.2) | 5 (62.5) | 22 (20.7) | ||
| Pretreatment Ki67 index | 0.005b | 0.10c | |||||
| < 14% | 32 (29.6) | 6 (14.0) | 25 (39.1) | 0 (0) | 32 (32.0) | ||
| ≥ 14% | 76 (70.4) | 37 (86.0) | 39 (60.9) | 8 (100.0) | 68 (68.0) | ||
Abbreviations: ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; PR, progesterone receptor; SD, standard deviation.
Notes: Data are presented as numbers and percentages, unless otherwise indicated.
a
Mann-Whitney test.
b
Chi-squared test.
c
Fisher exact test.
*
Missing data: histological subtype (n = 2; 0.02%); histological grade (n = 3; 0.03%); initial tumor (T) staging (n = 3; 0.03%); PR (n = 3; 0.03%); HER2 status (n = 1; 0.008%); pretreatment Ki67 (n = 7; 0.06%); clinical complete response (n = 2; 0.02%); percentage of cells with ER expression (n = 2; 0.02%); percentage of cells with PR expression (n = 2; 0.02%).